Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
MYCN is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. De plus, nous expédions MYCN Protéines (10) et MYCN Kits (6) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 96 products:
Human Monoclonal MYCN Primary Antibody pour ChIP, CyTOF - ABIN152254
Tasseva, Cole, Vance: N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells. dans The Journal of biological chemistry 2011
Show all 3 references for 152254
Mouse (Murine) Polyclonal MYCN Primary Antibody pour ICC, IF - ABIN256650
Sjostrom, Finn, Hahn, Rowitch, Kenney: The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. dans Developmental cell 2005
Show all 2 references for 256650
Human Polyclonal MYCN Primary Antibody pour EIA, WB - ABIN453206
Alvarez-Rodríguez, Pons: Expression of the proneural gene encoding Mash1 suppresses MYCN mitotic activity. dans Journal of cell science 2009
Show all 2 references for 453206
Cow (Bovine) Polyclonal MYCN Primary Antibody pour WB - ABIN2779428
Hansford, Thomas, Keating, Burkhart, Peaston, Norris, Haber, Armati, Weiss, Marshall: Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. dans Proceedings of the National Academy of Sciences of the United States of America 2004
Human Polyclonal MYCN Primary Antibody pour IF (p), IHC (p) - ABIN760676
Ramraj, Aravindan, Somasundaram, Herman, Natarajan, Aravindan: Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. dans Oncotarget 2016
Human Polyclonal MYCN Primary Antibody pour WB - ABIN391590
Li, Sun, Chen, Squires, Nowroozizadeh, Liang, Huang: p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. dans Molecular cancer research : MCR 2015
LMO1 (Montrer LMO1 Anticorps) is an important oncogene (Montrer RAB1A Anticorps) that promotes neuroblastoma (Montrer ARHGEF16 Anticorps) initiation, progression, and widespread metastatic dissemination.
our results identify DOT1L (Montrer DOT1L Anticorps) as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma (Montrer ARHGEF16 Anticorps) oncogenesis. Furthermore, they characterize DOT1L (Montrer DOT1L Anticorps) inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma (Montrer ARHGEF16 Anticorps).
CCCTC-binding factor (CTCF (Montrer CTCF Anticorps)) targets the binding sites within MYCN promoter to facilitate its expression in neuroblastoma (Montrer ARHGEF16 Anticorps) (NB) cells.
PAX3 (Montrer PAX3 Anticorps)-FOXO1 (Montrer FOXO1 Anticorps) collaborates with MYCN during early rhabdomyosarcoma (RMS) tumourigenesis to dysregulate proliferation and inhibit myogenic differentiation and cell death.
The findings reveal a PLK1 (Montrer PLK1 Anticorps)-Fbw7 (Montrer FBXW7 Anticorps)-Myc (Montrer MYC Anticorps) signaling circuit that underlies tumorigenesis and validate PLK1 (Montrer PLK1 Anticorps) inhibitors, alone or with Bcl2 (Montrer BCL2 Anticorps) antagonists, as potential effective therapeutics for MYC (Montrer MYC Anticorps)-overexpressing cancers.
Results show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.
Rac (Montrer AKT1 Anticorps) activity may be an important determinant of metastatic capability in subsets of neuroblastoma (Montrer ARHGEF16 Anticorps) cells lacking MYCN amplification.
MYCN Gene Amplification is associated with Neuroblastoma (Montrer ARHGEF16 Anticorps).
MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK (Montrer ALK Anticorps)) is sufficient to induce neuroblastoma (Montrer ARHGEF16 Anticorps) (NB) in mouse sympathoadrenal cells
MYCN amplification can be heterogeneous between tumor sites, during tumor progression or following treatment, challenging the notion that MYCN copy number does not change for a particular neuroblastoma (Montrer ARHGEF16 Anticorps).
the role of N-myc in mouse lens development, was examined.
Using comparative genomic hybridization, authors found that NCC (Montrer SLC12A3 Anticorps)-derived NBL (Montrer NUMBL Anticorps) tumors in mice acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL (Montrer NUMBL Anticorps) including 17q gain, 2p gain and loss of 1p36.
a Mycn target gene encoding the miR (Montrer MLXIP Anticorps) cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.
ALKR1275Q cooperated with MYCN in the development of aggressive NB, possibly by downregulating the expression of ECM (Montrer MMRN1 Anticorps)/BM-associated genes and by conferring malignant potentials to MYCN-expressing cells.
Reuslts show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.
Thus, this synergistic effect of ZD55-shMYCN in combination with doxorubicin provides a novel therapy strategy for doxorubicin-resistant neuroblastoma (Montrer ARHGEF16 Anticorps), and is a promising approach for further clinical development.
demonstrate a critical link between Myc (Montrer MYC Anticorps)/Mycn gene activity and glycolysis in spermatogonial stem cell self-renewal
Loss of N-myc significantly impairs the Sonic hedgehog (Montrer SHH Anticorps) signaling pathway and disrupts the expression of cell cycle effectors with a significant reduction of Ccnd2 (Montrer CCND2 Anticorps).
Study shows that ground-state embryonic stem cells express low Myc (Montrer MYC Anticorps) levels. Deletion of both c-myc (Montrer MYC Anticorps) and N-myc activity strongly decreases transcription, splicing, and protein synthesis, leading to proliferation arrest; process is reversible and occurs without affecting pluripotency, suggesting that Myc (Montrer MYC Anticorps)-depleted stem cells enter a state of dormancy.
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.
N-myc proto-oncogene protein
, class E basic helix-loop-helix protein 37
, neuroblastoma MYC oncogene
, neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene
, oncogene NMYC
, v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
, Avian myelocytomatosis viral (v-myc) related oncogene neuroblastoma derived (Nmyc)
, Avian myelocytomatosis viral (v-myc) related oncogene, neuroblastoma derived (Nmyc)
, N-myc protein
, neuroblastoma myc-related oncogene 1